Indian court refuses to grant patent to drugs manufacturer in landmark case that could keep life-saving medicine affordable

 

Delhi

Health activists have welcomed a decision by India’s highest court not to grant a patent to a drugs manufacturer in a case campaigners say will help safeguard the ability of people around the world to afford life-saving medicine.

In what has been described a landmark case, the supreme court rejected a patent application by Novartis AG for a drug it claims was an updated anti-leukaemia treatment. Activists said the judgement would protect India’s £17bn generic drug industry, which makes cheaper, generic version of life-saving medicine.

“This is a ruling in favour of patients,” Leena Menghaney of Doctors Without Borders, told The Independent. “It will save the generic drugs industry. The impact will be felt in the decades to come.”

The dispute involving Novartis, a Swiss-based multi-national pharmaceutical company, dated back seven years and centred on its attempt to seek a patent for its anti-cancer drug Glivec. Glivec, which has been celebrated as a breakthrough in treating forms of blood cancer, costs £2,600 a month in its branded form while the generic version is available in India for just £48.

The company claimed the drug was a new product while activists said it was merely a slightly modified version of an earlier product whose patent had expired.

Activists said today’s ruling means other drug companies will also be prevented from obtaining patents on updated version of exiting drugs, a practise known as “ever-greening”. They said the impact will be felt around the world.

Pratibha Singh, a lawyer for Indian generics drug producer Cipla, part of an industry that is expected to be worth £46bn by 2010, told the AFP that the “ruling will have implications not just for India but also for other Asian, African and Latin American countries”.

She added: “The ruling also makes it clear you cannot patent a drug by just making some minor modifications — the key Section 3d of the patent law has been upheld by the court.”

India's generic drugs industry supplies around one-fifth of the world’s imitation drugs. It assumed this position because until 2005 it did not issue patents on drugs. It only did so to comply with rules laid down by the World Trade Organisation.

Novartis and other drug manufacturers argued that the patents are required to protect products that have required large sums in development research and testing.

Novartis said the ruling would “hinder medical progress”. It earlier told the Financial Times that it might halt supplies of the new medicine to India if the judgement went against the company.

“We strongly believe that original innovation should be recognised in patents to encourage investment in medical innovation especially for unmet medical needs,” said Ranjit Shahani, of Novartis India Limited. “We brought this case because we strongly believe patents safeguard innovation and encourage medical progress, particularly for unmet medical needs. This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options.”

Novartis’ application for a fresh patent in India was turned down by the country’s patent office in 2005. It then filed an appeal, saying that the new product could be more easily absorbed and therefore qualified as a new product. That appeal was in turn rejected so the company turned to the supreme court.

Kiran Hukku of the Cancer Patients Aid Association, an Indian NGO that helps people with cancer, said over the last three years it had helped provide generic drugs to around 5,000 cancer patients who were still alive as a result of the medicine.

 “So many lives will be saved as a result [of today’s ruling],” she said. “The medicine must come first.”

PROMOTED VIDEO
Have you tried new the Independent Digital Edition apps?
News
ebookA unique anthology of reporting and analysis of a crucial period of history
News
Ian Thorpe had Rio 2016 in his sights
people
Arts and Entertainment
Original Netflix series such as Orange Is The New Black are to benefit from a 'substantial' increase in investment
TVHoax announcement had caused outrage
Life and Style
Swimsuit, £245, by Agent Provocateur
fashion

Diving in at the deep end is no excuse for shirking the style stakes

News
One Direction star Harry Styles who says he has no plans to follow his pal Cara Delevingne down the catwalk.
peopleManagement confirms rumours singer is going it alone are false
Voices
Mrs Brown's Boy: D'Movie has been a huge commercial success
voicesWhen it comes to national stereotyping, the Irish know it can pay to play up to outsiders' expectations, says DJ Taylor
Arts and Entertainment
Curtain calls: Madani Younis
theatreMadani Younis wants the neighbourhood to follow his work as closely as his audiences do
Arts and Entertainment
'Deep Breath' is Peter Capaldi's first full-length adventure as the twelfth Doctor
TVFirst episode of new series has ended up on the internet
Life and Style
Douglas McMaster says the food industry is ‘traumatised’
food + drinkSilo in Brighton will have just six staple dishes on the menu every day, including one meat option, one fish, one vegan, and one 'wild card'
Sport
Mario Balotelli, Divock Origi, Loic Remy, Wilfried Bony and Karim Benzema
transfersBony, Benzema and the other transfer targets
Independent
Travel Shop
the manor
Up to 70% off luxury travel
on city breaks Find out more
santorini
Up to 70% off luxury travel
on chic beach resorts Find out more
sardina foodie
Up to 70% off luxury travel
on country retreats Find out more
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Web Developer (C#, ASP.NET, AJAX, JavaScript, MVC, HTML)

£40000 - £45000 per annum + Benefits + Bonus: Harrington Starr: Web Developer ...

C# R&D .NET Developer-Algorithms, WCF, WPF, Agile, ASP.NET,MVC

£50000 - £67000 per annum + Benefits + Bonus: Harrington Starr: C# R&D .NE...

C# Developer (Web, HTML5, CSS3, ASP.NET, JS, Visual Studios)

£40000 - £50000 per annum + Benefits + Bonus: Harrington Starr: C# Developer (...

C# Developer (ASP.NET, F#, SQL, MVC, Bootstrap, JavaScript)

£55000 - £65000 per annum + Benefits + Bonus: Harrington Starr: C# Developer (...

Day In a Page

Iraq crisis: How Saudi Arabia helped Isis take over the north of the country

How Saudi Arabia helped Isis take over northern Iraq

A speech by an ex-MI6 boss hints at a plan going back over a decade. In some areas, being Shia is akin to being a Jew in Nazi Germany, says Patrick Cockburn
The evolution of Andy Serkis: First Gollum, then King Kong - now the actor is swinging through the trees in Dawn of the Planet of the Apes

The evolution of Andy Serkis

First Gollum, then King Kong - now the actor is swinging through the trees in Dawn of the Planet of the Apes
You thought 'Benefits Street' was controversial: Follow-up documentary 'Immigrant Street' has got locals worried

You thought 'Benefits Street' was controversial...

Follow-up documentary 'Immigrant Street' has got locals worried
Refugee children from Central America let down by Washington's high ideals

Refugee children let down by Washington's high ideals

Democrats and Republicans refuse to set aside their differences to cope with the influx of desperate Central Americas, says Rupert Cornwell
Children's books are too white, says Laureate

Children's books are too white, says Laureate

Malorie Blackman appeals for a better ethnic mix of authors and characters and the illustrator Quentin Blake comes to the rescue
Blackest is the new black: Scientists have developed a material so dark that you can't see it...

Blackest is the new black

Scientists have developed a material so dark that you can't see it...
Matthew Barzun: America's diplomatic dude

Matthew Barzun: America's diplomatic dude

The US Ambassador to London holds 'jeans and beer' gigs at his official residence – it's all part of the job, he tells Chris Green
Meet the Quantified Selfers: From heart rates to happiness, there is little this fast-growing, self-tracking community won't monitor

Meet the 'Quantified Selfers'

From heart rates to happiness, there is little this fast-growing, self-tracking community won't monitor
Madani Younis: Five-star reviews are just the opening act for British theatre's first non-white artistic director

Five-star reviews are just the opening act for British theatre's first non-white artistic director

Madani Younis wants the neighbourhood to follow his work as closely as his audiences do
Mrs Brown and her boys: are they having a laugh?

Mrs Brown and her boys: are they having a laugh?

When it comes to national stereotyping, the Irish – among others – know it can pay to play up to outsiders' expectations, says DJ Taylor
Gavin Maxwell's bitter legacy: Was the otter man the wildlife champion he appeared to be?

Otter man Gavin Maxwell's bitter legacy

The aristocrat's eccentric devotion to his pets inspired a generation. But our greatest living nature writer believes his legacy has been quite toxic
Joanna Rowsell: The World Champion cyclist on breaking her collarbone, shattering her teeth - and dealing with alopecia

Joanna Rowsell: 'I wear my wig to look normal'

The World Champion cyclist on breaking her collarbone, shattering her teeth - and dealing with alopecia
Bill Granger recipes: Our chef gives raw ingredients a lift with his quick marinades

Bill Granger's quick and delicious marinades

Our chef's marinades are great for weekend barbecuing, but are also a delicious way of injecting flavour into, and breaking the monotony of, weekday meals
Germany vs Argentina World Cup 2014 preview: Why Brazilians don't love their neighbours Argentina any more

Anyone but Argentina – why Brazilians don’t love their neighbours any more

The hosts will be supporting Germany in today's World Cup final, reports Alex Bellos
The Open 2014: Time again to ask that major question - can Lee Westwood win at last?

The Open 2014

Time again to ask that major question - can Lee Westwood win at last?